<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" type="text/css" href="css/style-manual.css">
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
    <script src="js/script.js"></script>
</head>
<body>
<!--Navacef-------------------------------------------------------->
<div class="bodyDiv" id="idNavacef">
    <div class="w3-container w3-center w3-animate-left">
        <h2 class="mango">Navacef</h2>
    </div>
<b>Product Orientation & Presentation:</b><br>
<table class="table1">
 <tr>
    <th>Brand Name:</th>
    <th>Navacef.</th>
  </tr>
  <tr>
    <td>Generic:</td>
	<td>Cefaclor,<br>
Capsule : 250 mg<br>
Capsule : 500 mg,<br>
Drops 15m1 : 125mg 1.25m1,<br>
Suspension :125 mg/5ml
   </td> 
  </tr>
  <tr>
<td>Strength:
</td>
<td>--
</td>
</tr>
  <tr>
    <td>Dosage Form:</td>
    <td>Capsule<br>
Drops,<br>
Suspension.
   </td>
    
  </tr>
	 
  <tr>
    <td>Therapeutic Class:</td>
	<td>Antibiotic(Broad-spectrum, Bactericidal).</td>
    
    </tr>

   
  </tr>
	 
  <tr>
    <td>Sub Therapeutic class: </td>
	<td>---</td>
    
    </tr>
		
  
  <tr>
    <td>Commercial Pack & Accessories:</td>
	<td>Capsule : 250 mg<br>
Capsule : 500 mg,<br>
Drops 15m1 : 125mg 1.25m1,<br>
Suspension :125 mg/5ml
60& l00mI </td>
    
  </tr>
	 
   <tr>
    <td>Price (TP):</td>
    <td>--</td>
	
   </tr>	
	 
   <tr>
 
    <td>Flavour </td>
    <td>pineapple & orange mixed flavour(PFS,Drops)</td>
	 
  </tr>
  
  <tr>
 
    <td>Indication: </td>
    <td>&#x2022;   Respiratory Tract Infection (RTI): Pharyngitis.
Tonsilitis. Pneumonia. Bronchitis etc.<br>&#x2022;   Urinary Tract Infection (UTI): Pyelonephritis, Pyelitis, Nephritis. Cystitis. Urethritis etc.<br>&#x2022;   Skin & Soft Tissue Infection (SSTI).<br>&#x2022;   Otitis media.</td>
  </tr>
  
   <tr>
 
    <td>Pregnancy: </td>
    <td>
  </td>
	 
  </tr>
  <tr>
<td>Lactation: 
</td>
<td>
--
</td>
</tr>
   <tr>
 
    <td>Children: </td>
    <td>From 1 month age of children-BNF</td>
	 
  </tr>
  
   <tr>
 
    <td>Brand Name Justification: </td>
    <td> ----  </td>
	 
  </tr>
  
   <tr>
    <td>Brand Slogan: </td>
    <td> --- </td>
  </tr>
  <tr>
<td>Dosage & Administration: 
</td>
<td>

</td>
</tr>
<tr>
<td>Key Selling Points: 
</td>
<td>
&#x2022; 
</td>
</tr>
<tr>
<td>Target Doctor: 
</td>
<td>
--
</td>
</tr>
<tr>
<td>Side effects: 
</td>
<td>
&#x2022; 
</td>
</tr>
<tr>
<td colspan="4">
 </table>
<br>

<div class="a">
<strong>A drug with immunomodulating property:</strong> Besides highly effective boctericidal activiiy, Cefaclor enhances phagocytosis and bactericidal activity of granulocytes and macrophages and favorably modifies the cooperation of monocytes and T lymphocytes.(phagocytosis-Body এর একটা defence mechanism. এখানে phagocyte cell এর মাধ্যমে Bodyতে যে harmful particles আছে তা engulf করে) 
</div>

<div class="a">
<strong></strong>Cefaclor enhances the protective potential of the immune reaction while it also reduces the risk of immunogenic clinical complications such as persistent inflammatory
conditions and allergic and/or autoaggressive responses.
</div>
<br>

<div class="a">
<strong>Immunomodulating properties of cefaclor are useful in</strong><br>
&#x2022;   Infective exacerbations of chronic bronchitis (IECB)<br>
&#x2022;   Otitis media and Maxilary Sinusitis (caused by beta loctamase producing strains of H. influeza and Moraxella catarrhalis)<br>
&#x2022;   Acute Streptococcal Pharyngitis<br>
&#x2022;   Complicated and recurrent UTI<br>
&#x2022;   Pyelonephritis (caused by ampicillin resistant organisms; such as KlebsieIla spp.)
</div><br>

<div class="a">
<strong>Definition of Diseases:</strong><br>
<strong>&#x261E; Rhinitis: </strong>Inflammation of the nasal mucosal membrane<br>
<strong>&#x261E; Sinusitis:</strong> Inflammation of sinus<br>
<strong>&#x261E; Pharyngitis:</strong> Inflammation of Pharynx<br>
<strong>&#x261E; Laryngitis:</strong> Inflammation of larynx<br>
<strong>&#x261E; Bronchitis:</strong> Inflammation of Bronchus<br>
<strong>&#x261E; Bronchitis:</strong> Inflammation of the mucous membrane in the bronchial tubes.<br>
<strong>&#x261E; Pneumonia:</strong> Inflammation of Lungs<br>
<strong>&#x261E; Tonsillitis:</strong> Inflammation of tonsil<br>
<strong>&#x261E; Otitis Media:</strong> Inflammation of middle ear<br>
<strong>&#x261E; Nephritis:</strong> Inflammation of Kidneys.<br>
<strong>&#x261E; Pyelonephritis:</strong> Inflammation of pelvis and
nephrone of kidney.<br>
<strong>&#x261E; Cystitis:</strong> Inflammation of urinary bladder.<br>
<strong>&#x261E; Urethritis:</strong> Inflammation of urethra.<br>
<strong>&#x261E; Prostatitis:</strong> Inflammation of the prostate gland.<br>
<strong>&#x261E; Pyelitis:</strong> Inflammation of the renal pelvis.
</div><br>

<div class="a">
<strong>KSP:</strong><br>
<strong>&#x261E;</strong> Excellent activity against both gram-positive and gram-negative bacteria.<br>
<strong>&#x261E;</strong> Well accepted flavour for children(pineapple & orange mixed flavour)
</div>
<br>

<div class="a">Dosage & Administration:
<strong></strong>Navacef is administered orally.<br>
<strong>Adults:</strong> The usual adult dose is 250 mg every eight hours. For severe infections or those caused by less susceptible organisms, doses may be doubled. The elderly dose is as for adults.<br>
<strong>Children:</strong> The usual recommended daily dose for children is 20 mg/kg/day in divided doses every 8 hours. In more severe infections, otitis media and infections caused by less susceptible organisms, 40 mg/kg/day in divided doses are recommended with a maximum dosage of 1 gm/day. Safety and efficacy have not been established for use in infants aged less than one month.<br>

Navacef powder for suspension (125 mg/5 ml)<br>
&lt; 1 year (9 kg)	2.5 ml t.i.d.<br>
1-5 years (9-18 kg)	5.0 ml t.i.d.<br>
Over 5 years	10.0 ml t.i.d.<br>
In the treatment of β-haemolytic streptococcal infections, therapy should be continued for at least 10 days. B.I.D. <br>
Treatment Option: For the treatment of otitis media and pharyngitis, the
total daily dosage may be divided and administered every 12 hours.<br>
Patients Undergoing Haemodialysis: Haemodialysis shortens serum half-life by 25-30%. In patients undergoing regular haemodialysis, a loading dose of 250 mg - 1 gm administered prior to dialysis and a therapeutic dose of 250- 500 mg every six to eight hours maintained during interdialytic periods is recommended.
</div><br>

<div class="a">
<strong></strong>Dosage & Administration According to BNF 78 Dose of Cefaclor for any susceptible infections due to Gram- positive & Gram-negative bacteria is given below:<br>
</div><br>

<table class="table1">
<style>
table, th, td {
  border: 1px solid black;
  border-collapse: collapse;
}
th, td {
  padding: 5px;
  text-align: left;
}
</style>

 <tr>
    <th>Age Group</th>
    <th>In generl cases</th>
	<th>In severe cases</th>
  </tr>

  <tr>
 
    <td>1 to 11 months

    </td>
	
	<td>
    20 mg/kg daily in 3 divided doses.
alternatively 62.5mg 3 times daily
    </td>
	
	<td>

40 mg/kg daily In 3 divided
doses. alternatively 125mg 3
times daily
    
    </td>
	
	</tr>
	
	<td>1 yr to 4 years
    
    </td>
	<td>20 mg/kg daily In 3 divided doses.
alternatively 125 mg 3 times daily
    
    </td>
	<td>

40 mg/kg daily In 3 divided
doses. alternatively 250mg 3
times daily
    
    </td>
	
    </tr>

    <tr>
    <td>5 yrs to 11 years</td>
    <td>20 mg/kg daily In 3 divided doses. alternatively 250mg 3 times daily 
   </td>
   <td>
40 mg/kg daily In 3 divided
doses.
   </td>
  
  </tr>
	
   <tr>
      <td colspan="3">
Usual max. dose is 1 gm daily
     </td>
   </tr>
		
 </table>
<br>

<img src="img/Navacef-1.png" alt="" class="responsive-IMG" width="375" height="300"><br>

<img src="img/Navacef-2.png" alt="" class="responsive-IMG" width="375" height="300"><br>

<img src="img/Navacef-3.png" alt="" class="responsive-IMG" width="375" height="300"><br>
</div>   
<footer>
    <p>© 2024 Md. Nurullah. All rights reserved.</p>
</footer>
<center><div class="ovalEnd">The End-Navacef</div></center><!--End Line---->
</body>
</html>